LAG3 and neoplasm: Subgroup analysis based on tumor type indicated that higher expression of LAG3 was correlated with worse DFS in patients with ESCA (HR = 2.86, 95% CI 1.03–7.94, P = 0.044), KIRC (HR = 8.92, 95% CI 2.40–33.18, P = 0.001), LIHC (HR = 1.62, 95% CI 1.08–2.41, P = 0.019), PAAD (HR = 1.94, 95% CI 1.20–3.14, P = 0.007), and STAD (HR = 2.65, 95% CI 1.53–4.58, P < 0.001).